Drug Profile
Research programme: hepatitis C virus infection therapies - iTherX
Alternative Names: Hepatitis C ribozyme gene therapy - Immusol/Novartis; ITX 4520; ITX 7650; PCDHBLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Immusol
- Developer iTherX Pharmaceuticals
- Class Antibodies; Small molecules
- Mechanism of Action Hepatitis C virus envelope protein inhibitors; Membrane protein inhibitors; SCARB1 protein antagonists; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
- 22 Oct 2010 Preclinical development is ongoing USA